Therefore CDKs have attracted much attention in recent years as potential cancer therapeutic targets and selective CDK4/6 inhibitors which potently inhibit the G1 to S phase transition have established their role in the clinic for patients with advanced ER+ breast cancer [32]. Here, CDK4 is linked to breast carcinoma.